Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIGNATURE: Dovitinib in Pathway-Activated Tumors
NCT01831726Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dovitinib in solid tumor, hematologic malignancy, sponsored by Novartis. Started Aug 2013; status: completed.
02
Drugs
dovitinib
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT01831726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01831726.